OnKure Therapeutics, Inc. OKUR Net Interest Income
Net Interest Income at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s net interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s net interest income?
- OnKure Therapeutics, Inc. (OKUR) reported net interest income of $458K in Q1 2026.
- How has OnKure Therapeutics, Inc.'s net interest income changed year-over-year?
- OnKure Therapeutics, Inc.'s net interest income decreased by 57.4% year-over-year, from $1.08M to $458K.
- What is the long-term trend for OnKure Therapeutics, Inc.'s net interest income?
- Over 2 years (2023 to 2025), OnKure Therapeutics, Inc.'s net interest income has grown at a 45.4% compound annual growth rate (CAGR), from $1.62M to $3.43M.
- What does net interest income mean?
- This metric represents the net financial result derived from interest-bearing assets and liabilities, calculated as total interest income minus total interest expense. For a clinical-stage biopharmaceutical company, it reflects the efficiency of treasury management and the yield generated from cash reserves held to fund ongoing research programs. A positive value indicates that the company is effectively earning a return on its capital, which helps offset a portion of its operating cash burn.